Plain-English translation of NCT07200193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called CRMA-1001, which is a type of gene therapy designed to help the body's own immune system fight chronic hepatitis B. Researchers will give participants different doses of this medication through an IV infusion to see how safe it is, how well it works, and how the body handles it. You would continue taking your regular hepatitis B antiviral medications throughout the study.
Chronic hepatitis B is a long-lasting infection that can damage the liver over time, and current treatments don't work for everyone. This trial is exploring whether this new gene therapy approach could offer a better way to help control or potentially cure the infection.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the medication at a research clinic — some participants get a single dose, while others get multiple doses over time. The study tracks how the medication affects your body through blood tests and other safety monitoring. You'll remain on your current hepatitis B medications throughout the study, and the research team will closely watch for any side effects or changes in your condition.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
France
Hong Kong
New Zealand
United Kingdom